Abstract

RNA Printer to Answer Increasing Demands for GMP-Grade mRNA Material

Martin Winter, Senior Director Strategic Marketing, Curevac AG

New approaches for personalized cancer therapies and fast responses to pandemics require rapid manufacturing of mRNA material. GMP-grade mRNA manufacturing normally is time consuming, expensive and requires extensive and specialized laboratories as well as highly qualified staff. To answer this demand, CureVac has developed an mRNA manufacturing platform, the mRNA Printer, for automated and integrated manufacturing of GMP-grade vaccines and therapeutics, engineered in collaboration with Tesla Automation. The system covers all steps for standardized and fast production of mRNA material and herewith facilitates broad access to mRNA technology and speeds up the process from research to therapy. The RNA Printer is capable to produce several grams of LNP-formulated mRNA within a few weeks and can be switched from one mRNA product to another in a short time. Due to its modular design, the platform is mobile and will therefore enable local manufacturing of mRNA medicines.